We are live on
!
Find out more
CAG
Crestwood Advisors Group Portfolio holdings
AUM
$5.94B
1-Year Est. Return
18.44%
This Fund
S&P 500
This Quarter
Est. Return
+3.51%
1 Year Est. Return
+18.44%
3 Year Est. Return
+65.91%
5 Year Est. Return
+80.01%
10 Year Est. Return
+299.27%
AUM
$1.03B
AUM Growth
+$197M
(+24%)
Cap. Flow
+$171M
Cap. Flow
% of AUM
16.54%
Top 10 Holdings %
Top 10 Hldgs %
29.34%
Holding
169
New
40
Increased
49
Reduced
53
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$18.6M |
| 2 |
Cognizant
CTSH
|
+$10.8M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$4.7M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$3.72M |
| 5 |
Visa
V
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$15.6M |
| 2 |
Union Pacific
UNP
|
+$2.53M |
| 3 |
State Street
STT
|
+$1.24M |
| 4 |
Medtronic
MDT
|
+$1.21M |
| 5 |
iShares Morningstar US Equity ETF
ILCB
|
+$925K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.62% |
| 2 | Technology | 9.64% |
| 3 | Healthcare | 8.81% |
| 4 | Consumer Discretionary | 7.13% |
| 5 | Consumer Staples | 5.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BRKL
126
DELISTED
Brookline Bancorp
BRKL
| $208K | 0.02% |
12,665
+1
| +0% | +$14 |
|
127
Oracle
ORCL
$345B
| $207K | 0.02% |
5,381
+195
| +4% | +$7.63K |
|
128
Lifecore Biomedical
LFCR
$163M
| $189K | 0.02% |
13,688
-1,980
| -13% | -$27.4K |
|
|
AGEN
129
Agenus
AGEN
$255M
| $136K | 0.01% |
1,678
| – | – |
|
130
Iovance Biotherapeutics
IOVA
$2.19B
| $87K | 0.01% |
+12,500
| New | +$86K |
|
131
Perspective Therapeutics
CATX
$322M
| $32K | ﹤0.01% |
5,482
| – | – |
|
|
PTN
132
Palatin Technologies
PTN
$13.9M
| $13K | ﹤0.01% |
+20
| New | +$13.9K |
|
|
SPRT
133
DELISTED
support.com, Inc.
SPRT
| $13K | ﹤0.01% |
5,000
| – | – |
|
|
CDMO
134
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $11K | ﹤0.01% |
5,000
| – | – |
|
135
Bristol-Myers Squibb
BMY
$128B
| – | – |
-3,836
| Closed | -$207K |
|
136
CVS Health
CVS
$137B
| – | – |
-4,464
| Closed | -$397K |
|
137
Diageo
DEO
$47.3B
| – | – |
-1,725
| Closed | -$200K |
|
|
138
Target
TGT
$63.7B
| – | – |
-226,850
| Closed | -$15.6M |
|
|
UN
139
DELISTED
Unilever NV New York Registry Shares
UN
| – | – |
-4,912
| Closed | -$226K |
|
Similar funds
AL
CGPCS
BP
WAM
GFM
VAM
TCM
CM
Crestwood Advisors Group's Q4 2016 Portfolio in Review
As of Q4 2016, Crestwood Advisors Group held 169 positions worth $1.03B, up 24% from $836M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Crestwood Advisors Group deployed $171M of net new capital in Q4 2016, opening 40 new positions and adding to 49 existing holdings. Its largest new stake was Cognizant: 201,362 shares worth $11.3M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 16% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Union Pacific, an estimated $2.53M trimmed.
- Crestwood Advisors Group's largest Q4 2016 buy was Cognizant: 201,362 shares worth $11.3M.
- Crestwood Advisors Group added most to State Street SPDR S&P 500 ETF Trust in Q4 2016, an estimated $18.6M increase.
- Crestwood Advisors Group's biggest Q4 2016 reduction was Union Pacific, cutting an estimated $2.53M.
- Crestwood Advisors Group fully exited Target in Q4 2016, selling an estimated $15.6M.
- Crestwood Advisors Group's ten largest holdings make up 29% of its $1.03B portfolio in Q4 2016.
- Crestwood Advisors Group opened 40 new positions and closed 5 in Q4 2016.
- Crestwood Advisors Group's portfolio value rose 24% quarter-over-quarter to $1.03B.
Based on Crestwood Advisors Group's 13F filing for Q4 2016, filed 12 Jan 2017.